Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

Jesús Garciá-Foncillas, E. Alba, E. Aranda, E. Diáz-Rubio, R. López-López, J. Tabernero, A. Vivancos

Research output: Contribution to journalReview articleResearchpeer-review

28 Citations (Scopus)

Abstract

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.
Original languageEnglish
Pages (from-to)2943-2949
JournalAnnals of Oncology
Volume28
Issue number12
DOIs
Publication statusPublished - 1 Dec 2017

Keywords

  • Colorectal cancer
  • EGFR
  • Liquid biopsy
  • Mutation testing
  • Tumor resistance

Fingerprint Dive into the research topics of 'Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review'. Together they form a unique fingerprint.

Cite this